Mildronate (Meldonium Dihydrate)

Meldonium, the active ingredient in Mildronate, is a pharmaceutical agent presented as an injectable solution for intravenous use. It modulates myocardial energy metabolism and is employed in the management of ischemic heart disease, angina pectoris and heart failure in adult patients.

GNH USA supplies Mildronate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards.

Mildronate (meldonium) is used to treat cardiovascular conditions that involve compromised myocardial energy supply.

Ischemic heart disease: improves cardiac energy efficiency and reduces ischemic injury. Angina pectoris: alleviates chest pain by enhancing myocardial perfusion. Heart failure: supports ventricular function by increasing fatty‑acid oxidation and glucose utilization.

Mildronate may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: transient gastrointestinal upset. - Injection site pain: localized discomfort after intravenous administration.

Serious or Rare Side Effects: - Arrhythmia: irregular heart rhythm requiring medical attention. - Severe hypotension: marked drop in blood pressure. - Anaphylactic reaction: rapid onset of allergic symptoms such as rash, swelling, and breathing difficulty.

When prescribing Mildronate, clinicians should consider several precautionary measures to ensure safe use.

Cardiac assessment: evaluate baseline cardiac function and ischemic status. Blood pressure monitoring: observe for hypotensive episodes during therapy. Liver function: check hepatic enzymes before and during treatment. Renal function: adjust use in patients with severe renal impairment. Hypersensitivity: discontinue if allergic reaction occurs. Store at ambient temperature: keep in original container, protect from moisture and light.

Mildronate can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - High‑dose carnitine supplements: may counteract Meldonium’s metabolic effect. - Potent vasodilators: additive hypotensive risk. - Certain anti‑arrhythmic agents: potential for synergistic cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: monitor heart rate and blood pressure. - ACE inhibitors: watch for enhanced blood‑pressure lowering. - Diuretics: assess electrolyte balance. - Anticoagulants: observe for bleeding tendency. - Statins: monitor liver enzymes.